New drug authorized against Alzheimer’s disease: hopes and uncertainties

Aduhelm, produced by the Biogen laboratory, is the first drug against Alzheimer’s disease to have received marketing authorization in the United States since 2003. It is also the first to tackle the causes of the disease. But for part of the scientific community, its benefit for patients has not been demonstrated.